NEW DLEHI : Roche India today announced that the Central Drugs Standards Control Organisation (CDSCO) has given an emergency authorisation for the antibody cocktail developed by US-based Regeneron for treatment of covid-19.An antibody cocktail is mixture of two or more unique biological drugs that act like human antibodies in the immune system, and thereby fight the disease.The authorisation in India will allow Roche to import the manufactured batches of the antibody cocktail of casirivimab and imdevimab, which will be marketed and distributed in India through a strategic partnership with Cipla Ltd.
Cipla is already the exclusive importer and distributor of tocilizumab, for which Roche has the patent.Roche India said that it will do.